T. Rowe Price Associates’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $264K | Buy |
|
|||||
|
2024
Q4 | – | Sell |
|
|||||
|
2024
Q3 | $201K | Buy |
|
|||||
|
2024
Q2 | $93K | Sell |
|
|||||
|
2024
Q1 | $168K | Buy |
|
|||||
|
2023
Q4 | $151K | Buy |
|
|||||
|
2023
Q3 | $109K | Buy |
|
|||||
|
2023
Q2 | $128K | Sell |
|
|||||
|
2023
Q1 | $149K | Buy |
|
|||||
|
2022
Q4 | $163K | Hold |
|
|||||
|
2022
Q3 | $129K | Sell |
|
|||||
|
2022
Q2 | $190K | Buy |
|
|||||
|
2022
Q1 | $248K | Buy |
|
|||||
|
2021
Q4 | $144K | Sell |
|
|||||
|
2021
Q3 | $210K | Buy |
|
|||||
|
2021
Q2 | $247K | Buy |
|
|||||
|
2021
Q1 | $150K | Buy |
|
|||||
|
2020
Q4 | $41K | Sell |
|
|||||
|
2020
Q3 | $30K | Hold |
|
|||||
|
2020
Q2 | $23K | Sell |
|
|||||
|
2020
Q1 | $6.15M | Buy |
|
|||||
|
2019
Q4 | $8.19M | Buy |
|
|||||
|
2019
Q3 | $7.13M | Sell |
|
|||||
|
2019
Q2 | $13.3M | Buy |
|
|||||
|
2019
Q1 | $13.1M | Buy |
|
|||||
|
2018
Q4 | $10.5M | Buy |
|
|||||
|
2018
Q3 | $14.6M | Buy |
|
|||||
|
2018
Q2 | $10M | Buy |
|
|||||
|
2018
Q1 | $9.51M | Buy |
|
|||||
|
2017
Q4 | $10.4M | Sell |
|
|||||
|
2017
Q3 | $7.06M | Buy |
|
|||||
|
2017
Q2 | $6.44M | Sell |
|
|||||
|
2017
Q1 | $9.12M | Buy |
|
|||||
|
2016
Q4 | $4.08M | Buy |
|
|||||
|
2016
Q3 | $3.58M | Buy |
|
|||||
|
2016
Q2 | $469K | Hold |
|
|||||
|
2016
Q1 | $438K | Sell |
|
|||||
|
2015
Q4 | $641K | Sell |
|
|||||
|
2015
Q3 | $549K | Buy |
|
|||||
|
2015
Q2 | $713K | Hold |
|
|||||
|
2015
Q1 | $793K | Buy |
|
|||||
|
2014
Q4 | $493K | Hold |
|
|||||
|
2014
Q3 | $421K | Hold |
|
|||||
|
2014
Q2 | $788K | Buy |
|
|||||
|
2014
Q1 | $613K | Buy |
|
|||||
|
2013
Q4 | – | Sell |
|
|||||
|
2013
Q3 | $16.5M | Sell |
|
|||||
|
2013
Q2 | $16.6M | Buy |
|